

DIGIRAD CORP
Form 10-Q
October 28, 2010
[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**
FOR THE TRANSITION PERIOD FROM TO

Commission file number: 000-50789

Digirad Corporation

Edgar Filing: DIGIRAD CORP - Form 10-Q

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction of Incorporation or Organization)

33-0145723
(I.R.S. Employer Identification No.)

13950 Stowe Drive, Poway, CA
(Address of Principal Executive Offices)

92064
(Zip Code)

(858) 726-1600

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☐

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐

Non-accelerated filer ☒ (Do not check if a smaller reporting company) Smaller reporting company ☐

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☐ No ☒

As of October 21, 2010, the registrant had 19,160,946 shares of Common Stock (\$0.0001 par value) outstanding.

Table of Contents

DIGIRAD CORPORATION

TABLE OF CONTENTS

<u>PART I. FINANCIAL INFORMATION</u>	3
<u>Item 1. Financial Statements</u>	3
<u>Consolidated Balance Sheets as of September 30, 2010 (Unaudited) and December 31, 2009</u>	3
<u>Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2010 and 2009</u>	4
<u>Unaudited Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2010 and 2009</u>	5
<u>Notes to Unaudited Consolidated Financial Statements</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	15
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	21
<u>Item 4. Controls and Procedures</u>	21
<u>PART II. OTHER INFORMATION</u>	23
<u>Item 1. Legal Proceedings</u>	23
<u>Item 1A. Risk Factors</u>	23
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	27
<u>Item 3. Defaults Upon Senior Securities</u>	27
<u>Item 4. Removed and Reserved</u>	28
<u>Item 5. Other Information</u>	28
<u>Item 6. Exhibits</u>	29
<u>SIGNATURES</u>	30
<u>EXHIBIT 31.1</u>	
<u>EXHIBIT 31.2</u>	
<u>EXHIBIT 32.1</u>	
<u>EXHIBIT 32.2</u>	

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****Digirad Corporation****Consolidated Balance Sheets****(In thousands, except share amounts)**

	September 30, 2010 (Unaudited)	December 31, 2009
Assets		
Current assets:		
Cash and cash equivalents	\$ 20,170	\$ 13,560
Securities available-for-sale	8,472	18,250
Accounts receivable, net	7,582	7,553
Inventories, net	6,051	6,402
Other current assets	1,174	1,234
Total current assets	43,449	46,999
Property and equipment, net	8,115	10,263
Intangible assets, net	910	1,243
Goodwill	184	184
Total assets	\$ 52,658	\$ 58,689
Liabilities and stockholders' equity		
Accounts payable	\$ 1,803	\$ 1,797
Accrued compensation	2,046	2,344
Accrued warranty	275	332
Other accrued liabilities	1,819	2,106
Deferred revenue	2,134	2,594
Total current liabilities	8,077	9,173
Deferred rent	198	127
Total liabilities	8,275	9,300
Commitments and contingencies (Note 10)		
Stockholders' equity:		
Preferred stock, \$0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding		
Common stock, \$0.0001 par value: 80,000,000 shares authorized; 18,562,872 and 18,476,293 shares issued and outstanding (net of treasury shares) at September 30, 2010 and December 31, 2009, respectively	2	2
Treasury stock, at cost; 573,218 shares and 547,418 shares at September 30, 2010 and December 31, 2009, respectively	(1,039)	(991)
Additional paid-in capital	154,583	153,867
Accumulated other comprehensive income	130	149
Accumulated deficit	(109,293)	(103,638)

Edgar Filing: DIGIRAD CORP - Form 10-Q

Total stockholders' equity	44,383	49,389
Total liabilities and stockholders' equity	\$ 52,658	\$ 58,689

See accompanying notes to consolidated financial statements.

Table of Contents**Digirad Corporation****Consolidated Statements of Operations****(Unaudited and in thousands, except per share data)**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Revenues:				
DIS	\$ 9,612	\$ 12,903	\$ 30,121	\$ 40,319
Product	3,687	4,025	11,405	12,878
Total revenues	13,299	16,928	41,526	53,197
Cost of revenues:				
DIS	7,941	9,563	24,912	29,285
Product	2,244	2,852	8,218	8,402
Total cost of revenues	10,185	12,415	33,130	37,687
Gross profit	3,114	4,513	8,396	15,510
Operating expenses:				
Research and development	683	864	2,278	2,490
Marketing and sales	1,389	1,698	4,569	5,422
General and administrative	2,417	2,139	6,817	6,783
Amortization of intangible assets	94	133	333	448
Restructuring loss		193	355	338
Total operating expenses	4,583	5,027	14,352	15,481
Income (loss) from operations	(1,469)	(514)	(5,956)	29
Other income (expense):				
Interest income	80	174	289	399
Interest expense	(1)	(2)	(5)	(7)
Other income (expense)	54	(72)	17	(7)
Total other income	133	100	301	385
Net income (loss)	\$ (1,336)	\$ (414)	\$ (5,655)	\$ 414
Net income (loss) per common share basic and diluted	\$ (0.07)	\$ (0.02)	\$ (0.30)	\$ 0.02
Weighted average shares outstanding basic	18,811	18,681	18,740	18,839
Weighted average shares outstanding diluted	18,811	18,681	18,740	19,289

See accompanying notes to consolidated financial statements.

Table of Contents

Digirad Corporation
Consolidated Statements of Cash Flows
(Unaudited and in thousands)

	Nine Months Ended September 30,	
	2010	2009
Operating activities		
Net income (loss)	\$ (5,655)	\$ 414
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:		
Depreciation	2,887	3,506
Amortization of intangible assets	333	448
Provision for bad debt	330	89
Stock-based compensation	688	461
Restructuring loss	355	338
Loss on disposal of assets	207	7
Amortization of premium on securities available-for-sale	247	312
Changes in operating assets and liabilities:		
Accounts receivable	(359)	677
Inventories	373	(1,754)
Other assets	60	644
Accounts payable	6	176
Accrued compensation	(466)	(621)
Other accrued liabilities	(721)	(1,313)
Net cash (used in) provided by operating activities	(1,715)	3,384
Investing activities		
Purchases of property and equipment	(1,205)	(641)
Proceeds from sale of property and equipment	55	980
Purchases of securities available-for-sale	(2,552)	(15,415)
Maturities of securities available-for-sale	12,065	11,851
Net cash provided by (used in) investing activities	8,363	(3,225)
Financing activities		
Issuances of common stock	46	7
Repurchases of common stock	(49)	(766)
Repayment of obligations under capital leases	(35)	(45)
Net cash used in financing activities	(38)	(804)
Net increase in cash and cash equivalents	6,610	(645)
Cash and cash equivalents at beginning of period	13,560	13,525
Cash and cash equivalents at end of period	\$ 20,170	\$ 12,880

See accompanying notes to consolidated financial statements.

Table of Contents

DIGIRAD CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. The Company

Digirad Corporation (Digirad), a Delaware corporation, is a leading developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. Digirad is also one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through its Digirad Imaging Solutions (DIS) division. Digirad has two reportable segments, DIS and Product. The accompanying consolidated financial statements include the operations of both segments. Intercompany accounts and transactions have been eliminated in consolidation. Substantially all of the Company's revenue arises from sales activity in the United States. Through DIS, the Company provides in-office leasing services to physicians, offering certified personnel, required licensure, an imaging system and other support and supplies for the performance of nuclear and ultrasound imaging procedures under the supervision of its physician customers. DIS physician customers enter into annual lease contracts for imaging services generally delivered on a per-day basis. The Company's Product segment sells solid-state gamma cameras and provides camera service and maintenance.

Note 2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of the Company's management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2010 are not necessarily indicative of the results that may be expected for the entire year. These consolidated financial statements were derived from and should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on February 12, 2010 from which the December 31, 2009 balance sheet information was derived.

Revenue Recognition

The Company derives revenue primarily from providing in-office services to support the performance of cardiac imaging procedures and from selling and servicing solid-state digital gamma cameras. The Company recognizes revenue in accordance with the authoritative guidance for revenue recognition, when all of the following four criteria are met: (i) a contract or sales arrangement exists; (ii) products have been shipped and title has transferred or services have been rendered; (iii) the price of the products or services is fixed or determinable; and (iv) collectability is reasonably assured. The timing of revenue recognition is based upon factors such as passage of title and risk of loss, the need for installation, and customer acceptance. These factors are based on the specific terms of each contract or sales arrangement.

DIS revenue is derived from the leasing of personnel and equipment for in-office nuclear and ultrasound imaging procedures. Revenue related to imaging services is recognized at the time services are performed and collection is reasonably assured. DIS services are generally billed on a per-day basis under annual contracts, which specify the number of days of service to be provided, or on a flat rate month-to-month basis.

Product revenues are generated from the sales of gamma cameras and follow-on maintenance service contracts. The Company generally recognizes revenue upon delivery to customers. The Company also provides installation and training for camera sales in the United States. Installation and training is generally performed shortly after delivery and represents a cost, which the Company accrues at the time revenue is recognized. Neither service is essential to the functionality of the product. Maintenance services are sold beyond the term of the warranty, which is generally one year from the date of purchase. Revenue from these contracts is deferred and recognized ratably over the period of the obligation and is included in product sales.

Table of Contents***Fair-value of Financial Instruments***

The authoritative guidance for fair value measurements defines fair value for accounting purposes, establishes a framework for measuring fair value and provides disclosure requirements regarding fair value measurements. The guidance defines fair value as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, assets and liabilities that are rarely traded or not quoted have less pricing observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its assets and liabilities measured at fair value into a three-level hierarchy in accordance with this guidance. See Note 5 for a further discussion regarding the Company's measurement of assets and liabilities at fair value.

Share-Based Compensation

The Company accounts for share-based awards exchanged for services in accordance with the authoritative guidance for share-based payments. Under this guidance, share-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense, net of estimated forfeitures, over the requisite service period.

Total share-based compensation expense related to all of the Company's share-based awards for the three and nine months ended September 30, 2010 and 2009 was allocated in the consolidated statements of operations as follows (in thousands, except per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Cost of revenues:				
DIS	\$ 5	\$ 6	\$ 22	\$ 20
Product	13	14	40	42
Research and development	13	9	40	27
Marketing and sales	27	21	77	70
General and administrative	280	94	509	302
Share-based compensation expense	\$ 338	\$ 144	\$ 688	\$ 461
Share-based compensation expense per share:				
Basic and diluted	\$ 0.02	\$ 0.01	\$ 0.04	\$ 0.02

Restructuring

Restructuring costs are included in loss from operations within the consolidated statements of operations. Restructuring loss for the nine months ended September 30, 2010 is comprised of one-time termination benefits for involuntarily terminated employees, write-offs of under utilized cameras and capital equipment and obligations pertaining to an abandoned property lease. Losses on property and equipment were recorded consistent with the Company's accounting policy related to long-lived assets. One-time termination benefits are recorded at the time they are communicated to the affected employees. Losses on property lease obligations are recorded when the lease is abandoned. See Note 7 for a further discussion regarding the Company's restructuring costs incurred as of September 30, 2010.

Table of Contents***Comprehensive Income (Loss)***

Comprehensive income (loss) consists of the following components (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Net income (loss), as reported	\$ (1,336)	\$ (414)	\$ (5,655)	\$ 414
Unrealized gain (loss) on marketable securities	72	36	(19)	177
Comprehensive income (loss)	\$ (1,264)	\$ (378)	\$ (5,674)	\$ 591

Note 3. Basic and Diluted Net Income (Loss) Per Share

Basic earnings per share (EPS) is calculated by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding. Diluted EPS is computed by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding and the weighted average number of dilutive common stock equivalents, including stock options and non-vested restricted stock units. Common stock equivalents are only included in the diluted earnings per share calculation when their effect is dilutive. Shares used to compute basic net income (loss) per share include 260,282 and 231,614 restricted stock units for the three and nine months ended September 30, 2010, respectively, compared to 64,756 and 35,325 for the three and nine months ended September 30, 2009, respectively.

The following table sets forth the computation of basic and diluted net income (loss) per share for the periods indicated (in thousands, except per share amounts):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Net income (loss)	\$ (1,336)	\$ (414)	\$ (5,655)	\$ 414
Shares used to compute basic net income (loss) per share	18,811	18,681	18,740	18,839
Dilutive potential common shares:				
Stock options				316
Restricted stock units				134
Shares used to compute diluted net income (loss) per share	18,811	18,681	18,740	19,289
Basic and diluted net income (loss) per share	\$ (0.07)	\$ (0.02)	\$ (0.30)	\$ 0.02

Since the Company incurred net losses for the three and nine months ended September 30, 2010 and three months ended September 30, 2009, 519,987, 572,885 and 450,200 common share equivalents were excluded from the computation of diluted earnings (loss) per share for the three and nine months ended September 30, 2010 and three months ended September 30, 2009, respectively, as their effect would be antidilutive.

Table of Contents**Note 4. Supplementary Balance Sheet Information (in thousands):**

	September 30, 2010	December 31, 2009
Inventories, net:		
Raw materials	\$ 2,738	\$ 3,431
Work-in-process	1,897	1,916
Finished goods	2,848	1,852
	7,483	7,199
Less reserve for excess and obsolete inventories	(1,432)	(797)
	\$ 6,051	\$ 6,402
Property and equipment, net:		
Machinery and equipment	\$ 21,915	\$ 22,440
Computer hardware and software	2,348	2,270
Leasehold improvements	807	764
	25,070	25,474
Accumulated depreciation	(16,955)	(15,211)
	\$ 8,115	\$ 10,263
Intangible assets, net:		
Customer relationships	\$ 2,600	\$ 2,600
Covenants not to compete	300	300
Patents	153	153
	3,053	3,053
Accumulated amortization of customer relationships	(1,866)	(1,588)
Accumulated amortization of covenants not to compete	(205)	(160)
Accumulated amortization of patents	(72)	(62)
	\$ 910	\$ 1,243
Other accrued liabilities:		
Radiopharmaceuticals and consumable medical supplies	\$ 404	\$ 323
Professional fees	362	338
Outside services and consulting	290	312
Travel expenses	174	165
Sales and property taxes payable	173	278
Facilities and related costs	138	218
Other accrued liabilities	278	472
	\$ 1,819	\$ 2,106

Note 5. Fair Value of Financial Instruments

The Company has categorized its assets and liabilities measured at fair value into a three-level hierarchy in accordance with the authoritative guidance for fair value measurements. Assets and liabilities measured at fair value using quoted prices in active markets for identical assets or

Edgar Filing: DIGIRAD CORP - Form 10-Q

liabilities are generally categorized as Level 1; assets and liabilities measured at fair value using observable market-based inputs or unobservable inputs that are corroborated by market data for similar assets or liabilities are generally categorized as Level 2; and assets and liabilities measured at fair value using unobservable inputs that cannot be corroborated by market data are generally categorized as Level 3. Assets and liabilities presented at fair value in the Company's consolidated balance sheets are generally categorized as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities. The Company has U.S. treasury securities which are valued based on publicly available quoted prices for identical securities as of December 31, 2009.

Table of Contents

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company's Level 2 assets as of September 30, 2010 and December 31, 2009 included its investments in government sponsored entities and corporate debt securities which were valued by a third party pricing vendor using proprietary valuation models (typically discounted cash flow models) and analytical tools. The inputs to these models related to similar instruments and were both objective and publicly available.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such assets and liabilities may have values determined using pricing models, discounted cash flow methodologies, or similar techniques, and include instruments for which the determination of fair value requires significant management judgment or estimation. The Company did not have any Level 3 assets or liabilities as of September 30, 2010 or December 31, 2009.

As required by the guidance for fair value measurements, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management's assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of assets and liabilities and their placement within the fair value hierarchy levels. The following table sets forth by level within the fair value hierarchy the Company's assets and liabilities that were recorded at fair value as of September 30, 2010 and December 31, 2009 (in thousands).

	At Fair Value as of September 30, 2010			
	Level 1	Level 2	Level 3	Total
Assets:				
Government sponsored entities	\$	\$ 505	\$	\$ 505
Corporate debt securities		7,967		7,967
Total	\$	\$ 8,472	\$	\$ 8,472

	At Fair Value as of December 31, 2009			
	Level 1	Level 2	Level 3	Total
Assets:				
U.S. treasury securities	\$ 4,066	\$	\$	\$ 4,066
Municipal bonds		103		103
Government sponsored entities		3,913		3,913
Corporate debt securities		10,168		10,168
Total	\$ 4,066	\$ 14,184	\$	\$ 18,250

The Company's investments in U.S. treasuries were valued based on publicly available quoted prices for identical securities as of December 31, 2009. The Company's government sponsored entities, corporate debt securities and municipal debt securities are valued by a third party pricing vendor using proprietary valuation models (typically discounted cash flow model) and analytical tools. The inputs to these models related to similar instruments and were both objective and publicly available. Such investments are therefore considered to be Level 2 items. Assets in the tables above are reported in the consolidated balance sheets as components of securities available for sale.

Cash Equivalents

The Company considers all investments with an original maturity of three months or less when acquired to be cash equivalents. Cash equivalents primarily are investments in money market funds whose cost equals fair market value.

Table of Contents***Securities Available for Sale***

As of September 30, 2010 and December 31, 2009, all of the Company's securities available for sale primarily consist of U.S. treasury securities, high-grade corporate debt securities and obligations of government sponsored entities. The Company classifies all securities as available for sale, as the sale of such securities may be required prior to maturity to implement management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of other comprehensive income (loss) in stockholder's equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis and are included in other income within the consolidated statements of operations. The amortization, accretion and interest income are included in interest income within the consolidated statements of operations. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in a revaluation of its carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. As of September 30, 2010 and December 31, 2009, none of the Company's investments have been in an unrealized loss position for more than 12 months. Premiums and discounts on debt securities are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method. Interest income is recognized when earned.

The following table sets forth the composition of securities available for sale as of September 30, 2010 and December 31, 2009 (in thousands):

As of September 30, 2010	Maturity in Years	Amortized Cost	Unrealized		Fair Value
			Gains	Losses	
Government sponsored entities	3 or less	\$ 504	\$ 1	\$	\$ 505
Corporate debt securities	4 or less	7,838	153	(24)	7,967
Total:		\$ 8,342	\$ 154	\$ (24)	\$ 8,472

As of December 31, 2009	Maturity in Years	Amortized Cost	Unrealized		Fair Value
			Gains	Losses	
U.S. treasury securities	2 or less	\$ 4,050	\$ 16	\$	\$ 4,066
Municipal bonds	3 or less	102	1		103
Government sponsored entities	3 or less	3,912	6	(5)	3,913
Corporate debt securities	4 or less	10,037	155	(24)	10,168
Total:		\$ 18,101	\$ 178	\$ (29)	\$ 18,250

Note 6. Warranty

The Company provides a warranty on certain of its products and accrues the estimated cost at the time revenue is recorded. Warranty expense is charged to Product cost of revenues. Substantially all of the warranty periods are 12 months before customer-sponsored maintenance programs begin. Warranty reserves are established based on historical experience with failure rates and repair costs and the number of systems covered by warranty. Warranty reserves are depleted as the Company's gamma cameras are repaired. The costs consist primarily of materials, personnel, and overhead. The Company reviews warranty reserves quarterly and, if necessary, makes adjustments.

The Company's activities within the warranty reserve consisted of the following (in thousands):

Three Months Ended September 30,		Nine Months Ended September 30,	
2010	2009	2010	2009

Edgar Filing: DIGIRAD CORP - Form 10-Q

Balance at beginning of period	\$ 277	\$ 736	\$ 332	\$ 906
Charges to cost of revenues	150	48	459	372
Costs applied to liability	(152)	(252)	(516)	(746)
Balance at end of period	\$ 275	\$ 532	\$ 275	\$ 532

Table of Contents**Note 7. Restructuring**

In response to the change in market conditions, which contributed to operating losses within the Company's DIS and Product business segments, the Company reduced its workforce during the second quarter of 2010. The reduction was designed to bring the Company's current operating expenses more in line with its revenues as a result of declines in reimbursement to its physician customers, worldwide medical isotope shortages and regulatory uncertainty in the healthcare system that is negatively affecting DIS and Product revenues. The Company continues its investment in on-going product and technology initiatives, as highlighted by the recent introduction of its ergo general purpose portable imaging system. The write-offs of cameras and capital equipment were due to lower headcount and demand within its consolidated operations. The Company incurred restructuring charges of approximately \$0.4 million, which included severance payments, write-offs of excess cameras and capital equipment and other related costs.

Restructuring activity through September 30, 2010 is comprised of the following (in thousands):

	2010 Charges	Cash Payments	Non-cash Settlements	Liability as of September 30, 2010	Total Costs Incurred as of September 30, 2010	Total Expected Costs as of September 30, 2010
Restructuring charges:						
Loss on property and equipment						
DIS	\$ 180	\$	\$ (180)	\$	\$ 180	\$ 180
Product						
Severance costs						
DIS	64	(73)	12	3	64	64
Product	88	(92)	4		88	88
Lease obligations						
DIS	23	(7)		16	23	23
Product						
Total restructuring charges	\$ 355	\$ (172)	\$ (164)	\$ 19	\$ 355	\$ 355

Restructuring activities are recorded in accordance with the authoritative guidance for exit and disposal activities. The costs are reported separately under restructuring loss on the consolidated statement of operations and are included in the income (loss) from operations within the Company's DIS and Product business segments as shown above. Severance costs are recorded at the time they are communicated to the affected employees. The losses pertained to property and equipment that were excess and written off during the quarter ended June 30, 2010 as further discussed in the previous paragraph. Losses on leased property at the hub locations are recorded when the lease is abandoned. The Company's restructuring plan was substantially completed by June 30, 2010.

Table of Contents**Note 8. Segments**

The Company's reporting segments have been determined based on the nature of the products and services offered to customers or the nature of their function in the organization. The Company evaluates performance based on the operating income contributed by each segment. The accounting policies of the reporting segments are the same as those described in the summary of significant accounting policies in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2010. Segment results are as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Gross profit by segment:				
DIS	\$ 1,671	\$ 3,340	\$ 5,209	\$ 11,034
Product	1,443	1,173	3,187	4,476
Consolidated gross profit	\$ 3,114	\$ 4,513	\$ 8,396	\$ 15,510
Income (loss) from operations by segment:				
DIS	\$ (869)	\$ 118	\$ (3,104)	\$ 1,299
Product	(600)	(632)	(2,852)	(1,270)
Consolidated income (loss) from operations	\$ (1,469)	\$ (514)	\$ (5,956)	\$ 29
Depreciation and amortization of tangible and intangible assets by segment:				
DIS	\$ 940	\$ 1,117	\$ 2,858	\$ 3,547
Product	122	126	362	407
Consolidated depreciation and amortization	\$ 1,062	\$ 1,243	\$ 3,220	\$ 3,954
Identifiable assets by segment:			As of September 30, 2010	As of December 31, 2009
DIS			\$ 15,034	\$ 18,067
Product			37,624	40,622
Consolidated assets			\$ 52,658	\$ 58,689

Note 9. Income Taxes

As of December 31, 2009, the Company had unrecognized tax benefits of approximately \$1.6 million. There has been no significant change in unrecognized tax benefits through September 30, 2010. Included in the unrecognized tax benefits of \$1.6 million at December 31, 2009 was \$1.3 million of tax benefits that, if recognized, would reduce the Company's annual effective tax rate, subject to the valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months.

The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company is no longer subject to income tax examination by tax authorities for years prior to 2003; however, its net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. The Company's policy is to recognize interest expense and penalties related to

Edgar Filing: DIGIRAD CORP - Form 10-Q

income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of September 30, 2010 and December 31, 2009.

Table of Contents

Note 10. Commitments and Contingencies

Acquisition

On May 1, 2007, the Company completed the acquisition of substantially all of the assets and liabilities of Ultrascan, Inc. ("Ultrascan"), a provider of ultrasound imaging systems and services to physicians' offices and hospitals. Additional consideration, payable in cash and common stock, of up to \$3.9 million would have been payable to the seller, or its designees, in the event that certain financial milestones were achieved over a four year period commencing on the date of the acquisition. In September 2010, the Company entered into two earnout release agreements for immaterial cash consideration, which released the Company from any future obligations under the asset purchase agreement prior to its original term.

Stock Repurchase Program

On February 4, 2009, the Company's board of directors authorized a stock buyback program to repurchase up to an aggregate of \$2.0 million of its issued and outstanding common shares. The timing and extent of the repurchase depends upon market conditions, applicable legal requirements, and other factors. During the three and nine months ended September 30, 2010, the Company repurchased zero and 25,800 shares of its common stock, respectively, under the stock buyback program. The repurchase of 25,800 shares cost less than \$0.1 million, at a weighted average price of \$1.92 per share, for the nine months ended September 30, 2010. Since the inception of the program, the Company has repurchased 573,218 shares of its common stock at a cost of \$1.0 million, at a weighted average price of \$1.79 per share.

Legal Matters

In the normal course of business, the Company has been, and will likely continue to be, subject to litigation or administrative proceedings incidental to its business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. As litigation and the administrative proceedings are inherently uncertain, the Company cannot predict the outcome of such matters. While the ultimate outcome of litigation is always uncertain, the Company does not believe that it will have a material adverse effect on its business or financial results.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our financial statements and notes thereto included in this report on Form 10-Q, and the audited financial statements and notes as of and for the year ended December 31, 2009 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2010. Operating results are not necessarily indicative of results that may occur in future periods.

This report contains various forward-looking statements regarding our business, financial condition, results of operations and future plans and projects. Forward-looking statements discuss matters that are not historical facts and can be identified by the use of words such as believes, expects, anticipates, estimates, can, could, may, will, would, might or similar expressions. In this report, for example, we make forward-looking statements regarding, among other things, our expectations about the rate of revenue growth in specific business segments and the reasons for that growth and our profitability, our expectations regarding an increase in sales, strategic traction and marketing and sales spending, uncertainties relating to our ability to compete, uncertainties relating to our ability to increase our market share, changes in coverage and reimbursement policies of third-party payers and the effect on our ability to sell our products and services, our ability to timely develop new products or services that will be accepted by the market, competition from alternative imaging modalities, declining average selling prices for our Product offerings, supplies of radiopharmaceuticals, and the profitability of our DIS core footprint.

Although these forward-looking statements reflect the good faith judgment of our management, such statements can only be based upon facts and factors currently known to us. Forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. As a result, our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under the caption Risk Factors. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You should not unduly rely on these forward-looking statements, which speak only as of the date on which they were made. They give our expectations regarding the future, but are not guarantees. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Overview

We are a leading developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. We also are one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through our Digirad Imaging Solutions (DIS). We designed and commercialized the first solid-state nuclear gamma camera for the detection of cardiovascular disease and other medical conditions. Our imaging systems are sold in both portable and fixed configurations, and provide enhanced operability, improved patient comfort and, in the case of our triple-headed Cardius® 3 XPO system, shorter image acquisition time when compared to traditional vacuum tube cameras or our single or dual headed cameras. Our nuclear cameras fit easily into floor spaces as small as seven feet by eight feet and facilitate the delivery of nuclear medicine procedures in a physician's office, an outpatient hospital setting or within multiple departments of a hospital, (e.g., emergency and operating rooms).

We generate revenues within two primary operating segments: our personnel and equipment leasing service business DIS and our Product segment. Through DIS, we offer a comprehensive personnel and equipment leasing services program as an alternative to purchasing a gamma camera or ultrasound equipment for physicians who wish to perform nuclear imaging, echocardiography, vascular ultrasound, or any combination of these procedures in their offices by leasing the imaging system, certified personnel and other support required to perform imaging in the physician's office. The flexibility of our products and our DIS leasing service allows physicians more control over the diagnosis and treatment of their patients in their offices and to retain revenue from procedures they would otherwise refer elsewhere. DIS leasing services are primarily provided to cardiologists, internal medicine physicians and family practice doctors who enter into annual contracts for personnel and equipment services delivered on a per-day basis. Our typical lease contracts provide service coverage ranging from once per month to five times per week. We experience some seasonality in our DIS business related to vacations, holidays and inclement weather. We are experiencing a significant market change due to the decline in reimbursements to our physicians and the uncertainty with healthcare legislation. This market change may require further changes to our business model in order for our physician customers and us to maintain a viable economic model. Our Product revenue results primarily from selling solid-state gamma cameras and camera maintenance contracts. We sell our imaging systems to physician offices, hospitals, and imaging centers primarily in the United States, although we have sold a small number of imaging systems internationally. As a result of the healthcare environment trends, we introduced a new product in 2009 called our Cardius® X-ACT camera, which is a rapid cardiac SPECT/VCT imager. The Cardius® X-ACT camera is positioned

Table of Contents

more toward the hospital and larger cardiology practices. In June 2010, we introduced our new ergo general purpose portable imaging system, which is targeted to hospital customers.

Our Market

The target market for our products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear cardiac and ultrasound procedures. As of September 30, 2010, we have provided imaging services through DIS to more than 1,100 physicians and physician groups. We have sold over 660 cameras through our Product segment. More than half of our DIS nuclear and ultrasound imaging customers are internal medicine physicians or other primary care practitioners, and the remainder are primarily cardiologists. Our market has been negatively affected, particularly this year, by declining reimbursements, pricing pressures, decreases in radiopharmaceutical isotope supplies and continuing efforts by some third party payers to reduce health care expenditures by requiring physicians to obtain specific accreditations or certifications. We are addressing these market pressures by introducing new products, such as our Cardius® X-ACT and ergo cameras and modifying our DIS business model. We anticipate introducing other new products and services in 2011 and beyond.

Trends and Drivers

The medical device industry, including the market for nuclear and ultrasound imaging systems and services, is highly competitive. Our business continues to be affected by many factors, including declining healthcare reimbursement rates for cardiac imaging procedures, competition from alternative imaging modalities such as positron emission tomography (PET) and computed tomography (CT) angiography, competition from other small owner-operated mobile nuclear imaging providers, declining average selling prices for our product offerings, general uncertainty in the healthcare marketplace and unpredictable availability of radiopharmaceuticals. We expect most of these trends to continue in the foreseeable future. In 2009, we began to experience a decline in demand for our cameras, partially due to very limited hospital and physician group capital budgets, in addition to uncertainties related to upcoming changes in healthcare regulations and economic conditions. This trend has continued into 2010.

Our physicians incurred a significant reimbursement reduction on January 1, 2010, which has impacted their businesses (reduced the profitability of our services) and our business (reduced the number of days that we scanned and reduced the price that we charge for a day of service). Furthermore, the severe winter weather in the east and midwest reduced the number of scan days in the first quarter of 2010 and the worldwide medical radiopharmaceutical shortage reduced the number of scan days in the second and third quarters of 2010. Also, the uncertainty over the enactment of future legislation that may impact reimbursement rates continues to linger and cause concern with our physician customers. We are building and modifying our business model to adapt to environmental and regulatory changes in the healthcare marketplace.

In our Product segment, we continue to build on past Product segment achievements by introducing new products targeted specifically at the larger physician practices and hospital market segments. In 2009, we received U.S. Food and Drug Administration (FDA) 510(k) clearance for our new Cardius® X-ACT imaging system. In late 2009, we introduced a new product called c*pax, a complete on-line fee-per-study cardiovascular information system, as a potential add-on companion for any of our nuclear cameras or ultrasound equipment. In June 2010, we introduced our new ergo general purpose portable imaging system, which is targeted to hospital customers. The ergo system is designed to take images of the inside of a patient's body using radioactive isotopes. The ergo system can be moved around the hospital so patients who cannot be taken to a nuclear medicine department can still be scanned. It includes a detector with a 12.5-inch-by-15.5-inch field of view.

First Nine Months of 2010 Financial Highlights

Our consolidated revenues were \$41.5 million during the nine months ended September 30, 2010, which represented a decrease of \$11.7 million, or 21.9%, over the comparable prior year period primarily due to a decrease in revenue from our DIS segment. DIS revenue decreased \$10.2 million, or 25.3%, due to a reduction in our daily lease fee combined with a reduction in the number of scan days. We reduced our daily lease fee to provide more incentive to our physician customers. Our physician customers reduced their scan days in part due to the lack of availability of radiopharmaceutical supply. The worldwide shortage of radiopharmaceuticals ended in August 2010 as expected, as the main reactor of medical isotopes (the Chalk River reactor in Canada) came back on-line. Additionally, Product revenues for the nine months ended September 30, 2010 also decreased by \$1.5 million, or 11.4%, compared to the prior year period, primarily due to a reduction in the number of cameras which were sold to cardiology practices and hospitals. The number of cameras sold decreased to 21 from 35 during the nine months ended September 30, 2010 and 2009, respectively.

We realized a loss from operations and a net loss for the nine months ended September 30, 2010 as a result of decreased DIS segment gross profits, despite our efforts to reduce our operating expenses. Our consolidated net loss for the nine months

Table of Contents

ended September 30, 2010 was \$5.7 million, compared to net income of \$0.4 million during the same period in the prior year. The decline in profitability in our DIS segment was primarily attributable to a reduction in our daily lease fee combined with a reduction in the number of days that our physician customers scanned patients. The decline in profitability in our Product segment was primarily attributable to a reduction in the number of cameras sold.

Our DIS business currently operates in 20 states. For the nine months ended September 30, 2010, DIS operated 68 nuclear gamma cameras and 65 ultrasound imaging systems, compared to 84 nuclear gamma cameras and 68 ultrasound imaging systems during the same period in the prior year. We are seeking to improve our overall profitability through more efficient utilization of our fleet of gamma cameras and ultrasound equipment. We measure efficiency by tracking system utilization, which is measured based on the percentage of days that our nuclear gamma cameras and ultrasound equipment are used to deliver services to customers out of the total number of days that they are available to deliver such services. System utilization decreased to 61.8% for the nine months ended September 30, 2010, compared to 63.2% during the same period in the prior year, primarily due to fewer scan days.

Results of Operations

The following table sets forth our results from operations expressed as percentages of revenues for the three and nine months ended September 30, 2010 and 2009:

	Three Months Ended September 30,				Change from Prior Year	
	2010	% of 2010 Revenues	2009	% of 2009 Revenues	Dollars	Percent
Revenues:						
DIS	\$ 9,612	72.3%	\$ 12,903	76.2%	\$ (3,291)	(25.5)%
Product	3,687	27.7%	4,025	23.8%	(338)	(8.4)%
Total revenues	13,299	100%	16,928	100%	(3,629)	(21.4)%
Total cost of revenues	10,185	76.6%	12,415	73.3%	(2,230)	(18.0)%
Gross profit	3,114	23.4%	4,513	26.7%	(1,399)	(31.0)%
Operating Expenses:						
Research and development	683	5.1%	864	5.1%	(181)	(20.9)%
Marketing and sales	1,389	10.4%	1,698	10.0%	(309)	(18.2)%
General and administrative	2,417	18.2%	2,139	12.6%	278	13.0%
Amortization of intangible assets	94	0.7%	133	0.8%	(39)	(29.3)%
Restructuring loss		0.0%	193	1.1%	(193)	(100.0)%
Total operating expenses	4,583	34.5%	5,027	29.7%	(444)	(8.8)%
Income (loss) from operations	(1,469)	(11.0)%	(514)	(3.0)%	(955)	185.8%
Other income	133	1.1%	100	0.6%	33	33.0%
Net income (loss)	\$ (1,336)	(10.0)%	\$ (414)	(2.4)%	\$ (922)	222.7%

Table of Contents

	Nine Months Ended September 30,				Change from Prior Year	
	2010	% of 2010 Revenues	2009	% of 2009 Revenues	Dollars	Percent
Revenues:						
DIS	\$ 30,121	72.5%	\$ 40,319	75.8%	\$ (10,198)	(25.3)%
Product	11,405	27.5%	12,878	24.2%	(1,473)	(11.4)%
Total revenues	41,526	100%	53,197	100%	(11,671)	(21.9)%
Total cost of revenues	33,130	79.8%	37,687	70.8%	(4,557)	(12.1)%
Gross profit	8,396	20.2%	15,510	29.2%	(7,114)	(45.9)%
Operating Expenses:						
Research and development	2,278	5.5%	2,490	4.7%	(212)	(8.5)%
Marketing and sales	4,569	11.0%	5,422	10.2%	(853)	(15.7)%
General and administrative	6,817	16.4%	6,783	12.8%	34	0.5%
Amortization of intangible assets	333	0.8%	448	0.8%	(115)	(25.7)%
Restructuring loss	355	0.9%	338	0.6%	17	5.0%
Total operating expenses	14,352	34.6%	15,481	29.1%	(1,129)	(7.3)%
Income (loss) from operations	(5,956)	(14.3)%	29	0.1%	(5,985)	(20,637.9)%
Other income	301	0.7%	385	0.7%	(84)	(21.8)%
Net income (loss)	\$ (5,655)	(13.6)%	\$ 414	0.8%	\$ (6,069)	(1,465.9)%

Comparison of Three Months Ended September 30, 2010 and 2009**Revenues**

Consolidated. Consolidated revenue was \$13.3 million for 2010, which represents a decrease of \$3.6 million, or 21.4%, compared to the prior year quarter, primarily as a result of extremely limited isotope supply in our DIS business segment and lower camera sales in our Product business segment. DIS revenue accounted for 72.3% of total revenues for 2010, compared to 76.2% for the prior year quarter. We expect DIS revenue to continue to represent the larger percentage of our consolidated revenue.

DIS. Our DIS revenue was \$9.6 million for the three months ended September 30, 2010, which represents a decrease of \$3.3 million, or 25.5%, compared to the prior year quarter. The decrease resulted from our decision to reduce our daily lease rate to physicians in response to the anticipated decline in nuclear reimbursements, along with a decrease in patient service days during the periods where supplies of radiopharmaceuticals were not available or available in short supply. With the passage of the recent healthcare reform legislation, the deferment of the sustainable growth rate until at least November 30, 2010 and the Chalk River Canadian nuclear reactor (supplies approximately 50 percent of the medical radiopharmaceuticals to North America) which came back in service in August 2010, we are working with our current and new physician customers to engage or re-engage our services.

Product. Our Product revenue was \$3.7 million for the three months ended September 30, 2010, which represents a decrease of \$0.3 million, or 8.4%, compared to the prior year quarter. The decrease in revenue resulted from a decrease in the number of gamma camera sales this year compared to the prior year quarter. We also introduced our new ergo general purpose portable imaging system in June 2010, which received a positive reception at the Society of Nuclear Medicine conference in Salt Lake City, and we believe, with this new solid state gamma camera, we will be effective in our efforts to penetrate the hospital marketplace in 2011 and beyond.

Edgar Filing: DIGIRAD CORP - Form 10-Q

Cost of Revenue and Gross Profit

Consolidated. Consolidated gross profit was \$3.1 million for the three months ended September 30, 2010, representing a decrease of \$1.4 million, or 31.0%, compared to the prior year quarter. The decrease in consolidated gross profit is primarily the result of the decline in DIS and Product revenues compared to the prior year period. The decreased revenues in DIS resulted in us reducing our labor costs and decreased cost of revenues in Product resulted from less cameras sold, both of which affected gross profit. Consolidated gross profit as a percentage of revenue decreased to 23.4% for the three months ended September 30, 2010 from 26.7% for the prior year quarter.

Table of Contents

DIS. Cost of DIS revenue consists primarily of labor, radiopharmaceuticals, equipment depreciation, and other costs associated with the provision of services. Cost of DIS revenue was \$7.9 million for the three months ended September 30, 2010, representing a decrease of \$1.6 million, or 17.0%, compared to the prior year quarter. The decrease in cost of DIS revenue is primarily a result of decreased radiopharmaceutical expenses from fewer scans. DIS gross profit was \$1.6 million for the three months ended September 30, 2010, which represents a decrease of \$1.7 million, or 50%, from a gross profit of \$3.3 million for the prior year quarter. DIS gross profit as a percentage of DIS revenue decreased to 17.4% for the three months ended September 30, 2010 from 25.9% for the prior year quarter. The decline in operational performance is primarily associated with the reduction in service days.

Product. Cost of Product revenue primarily consists of materials, labor and overhead costs associated with the manufacturing and warranty of our products. Cost of goods sold for the Product segment was \$2.2 million for the three months ended September 30, 2010, representing a decrease of \$0.6 million, or 21.3%, compared to the prior year quarter. The decrease in cost of Product revenue is primarily a result of lower camera sales during the current quarter and the mix of new and used cameras compared to the prior year quarter. Product gross profit was \$1.4 million for the three months ended September 30, 2010, representing an increase of \$0.3 million, or 23.0%, compared to the prior year period. Product gross profit as a percentage of Product revenue increased to 39.1% for the three months ended September 30, 2010 compared to 29.1% for the prior year quarter, primarily due to the mix of new and used cameras sold.

Operating Expenses

Research and Development. Research and development expenses are the costs associated with the design, development and enhancement of our products, and consist of salaries, development material costs, facility and overhead costs, consulting fees, and non-recurring engineering costs. We continue to invest in research and development with a focus on innovation as we seek to improve our existing technology. In 2009 and 2010, we received U.S. Food and Drug Administration 510(k) clearance for our new Cardius® X-ACT imaging system and ergo general purpose portable imaging system, respectively. Research and development expenses were \$0.7 million for the three months ended September 30, 2010, representing a decrease of \$0.2 million, or 20.9%, compared to the prior year quarter, primarily as a result of 2009 research and development efforts for the previously mentioned cameras, which did not reoccur in 2010. Research and development expenses were 18.5% of Product revenue for the three months ended September 30, 2010 compared to 21.5% in the prior year quarter, a decrease of 3.0%. We plan to continue investing in our technology platform to penetrate new and existing market segments and attract new customers.

Marketing and Sales. Marketing and sales expenses consist primarily of salaries, commissions, bonuses, recruiting costs, travel, marketing and collateral materials and trade show costs. Marketing and sales expenses were \$1.4 million for the three months ended September 30, 2010, representing a decrease of \$0.3 million, or 18.2%, compared to the prior year quarter, primarily as a result of lower personnel related costs due to lower camera sales. Marketing and sales expenses as a percentage of total revenues were 10.4% varying slightly from 10.0% for the three months ended September 30, 2010 and 2009, respectively.

General and Administrative. General and administrative expenses consist primarily of salaries and other related costs for accounting, human resources, information technology and executive personnel, legal related costs, professional fees, outside services, insurance, and costs related to our board of directors. General and administrative expenses were \$2.4 million for the three months ended September 30, 2010, representing an increase of \$0.3 million, or 13.0%, compared to the prior year quarter. This increase is primarily the result of increased share based compensation, bad debt reserves, legal and consulting services compared to the prior year period. General and administrative expenses were 18.2% of total revenue for the three months ended September 30, 2010 compared to 12.6% for the prior year quarter, mainly due to lower DIS revenue in 2010.

Restructuring Loss

In response to continued changing market conditions, which contributed to operating losses within our DIS and Product business segments, we reduced our workforce during the third quarter of 2009, which did not occur in the third quarter of 2010.

Comparison of Nine Months Ended September 30, 2010 and 2009

Revenues

Consolidated. Consolidated revenue was \$41.5 million for the nine months ended September 30, 2010, which represents a decrease of \$11.7 million, or 21.9%, from the prior year period, primarily as a result of extremely limited isotope supply in our DIS business segment and lower camera sales in our Product business segment. DIS revenue accounted for 72.5% of total revenues for the nine months ended September 30,

Edgar Filing: DIGIRAD CORP - Form 10-Q

2010, compared to 75.8% for prior year period. We expect DIS revenue to continue to represent the larger percentage of our consolidated revenue.

Table of Contents

DIS. Our DIS revenue was \$30.1 million for the nine months ended September 30, 2010, which represents a decrease of \$10.2 million, or 25.3%, from the prior year period. The decrease resulted from our decision to reduce our daily lease rate at the end of the first quarter to our physician customers in response to the anticipated decline in nuclear reimbursements, along with a decrease in patient service days during the periods where supplies of radiopharmaceuticals were not available or available in short supply.

Product. Our Product revenue was \$11.4 million for the nine months ended September 30, 2010, which represents a decrease of \$1.5 million, or 11.4%, compared to the prior year period. We believe that economic factors, including the uncertainty in the credit market and a slowing economy, as well as continued healthcare imaging reimbursement pressures resulted in decreased gamma camera sales.

Cost of Revenue and Gross Profit

Consolidated. Consolidated gross profit was \$8.4 million for the nine months ended September 30, 2010, representing a decrease of \$7.1 million, or 45.9%, compared to the prior year period. The decrease in consolidated gross profit is primarily the result of the decline in DIS and Product revenues as well as increased excess and obsolete inventory reserves compared to the prior year period. Consolidated gross profit as a percentage of revenue decreased to 20.2% for the nine months ended September 30, 2010 from 29.2% for the prior year period.

DIS. Cost of DIS revenue was \$24.9 million for the nine months ended September 30, 2010, representing a decrease of \$4.4 million, or 14.9%, from the prior year period, primarily due to decreased labor costs, decreased radiopharmaceutical expenses from fewer scans, and a reduction in depreciation costs. DIS gross profit was \$5.2 million for the nine months ended September 30, 2010, which represents a decrease of \$5.8 million, or 52.8% as compared to the prior year period. DIS gross profit as a percentage of DIS revenue decreased to 17.3% for the nine months ended September 30, 2010 from 27.4% for the prior year period. The decline in operational performance is primarily associated with the reduction in service days.

Product. Cost of goods sold was \$8.2 million for the nine months ended September 30, 2010, representing a slight decrease of \$0.2 million, or 2.2%, over the prior year period. Product gross profit decreased to \$3.2 million for the nine months ended September 30, 2010, representing a decrease of \$1.3 million, or 28.8%, compared to the prior year period. Product gross profit as a percentage of Product revenue decreased to 27.9% for the nine months ended September 30, 2010 from 34.8% for the prior year period primarily due to higher manufacturing variances from lower production volumes.

Operating Expenses

Research and Development. We continue to invest in research and development with a focus on innovation as we seek to improve our existing technology. In 2009 and 2010, we received U.S. Food and Drug Administration 510(k) clearance for our new Cardius® X-ACT imaging system and our new ergo general purpose portable imaging system, respectively. Research and development expenses were \$2.3 million for the nine months ended September 30, 2010, representing a decrease of \$0.2 million, or 8.5%, compared to the prior year period, primarily as a result of 2009 research and development efforts for the previously mentioned cameras, which did not reoccur in 2010. Research and development expenses were 20.0% and 19.3% of Product revenue for the nine months ended September 30, 2010 and 2009, respectively. We plan to continue investing in our technology platform to penetrate new and existing market segments and attract new customers.

Marketing and Sales. Marketing and sales expenses were \$4.6 million for the nine months ended September 30, 2010, which represents a decrease of \$0.9 million, or 15.7%, compared to the prior year period, primarily as a result of lower personnel costs. Marketing and sales expenses were 11.0% of total revenue for the nine months ended September 30, 2010 compared to 10.2% for the prior year period. The increased expenses as a percent of revenue are primarily due to the decline in DIS revenues.

General and Administrative. General and administrative expenses were \$6.8 million for the nine months ended September 30, 2010, which are consistent with the prior year period. General and administrative expenses were 16.4% of total revenue for the nine months ended September 30, 2010 compared to 12.8% for the prior year period. The increased expenses as a percent of revenue are primarily due to the decline in DIS revenues.

Restructuring Loss

Restructuring costs were \$0.4 million and \$0.3 million during the nine months ended September 30, 2010 and 2009, respectively. We initiated and substantially completed restructuring plans in the second quarter of 2010 and second and third quarters of 2009. During 2010 and 2009, we experienced changing market conditions, which contributed to operating losses within the our DIS and Product segments, including declines in

Edgar Filing: DIGIRAD CORP - Form 10-Q

reimbursements to our physician customers, worldwide isotope shortages and regulatory uncertainty in the healthcare system. In response, we reduced our workforce within both the Product and DIS segments in order to realign manufacturing and overhead expenses to a lower level of camera sales and consolidated certain DIS hub locations in order to focus on hub locations that have stronger anticipated margin and growth potential.

Table of Contents

Liquidity and Capital Resources

We require working capital principally to finance accounts receivable and inventory and for capital expenditures. Our working capital requirements vary from period to period depending on several factors, including our manufacturing volumes, the timing of our deliveries and the payment cycles of our customers. Our capital expenditures consist primarily of DIS nuclear cameras, ultrasound equipment, and vans to transport our people and equipment to customer locations.

As of September 30, 2010, we had cash, cash equivalents and securities available-for-sale of \$28.6 million. We currently invest our cash reserves in money market funds as well as government and corporate debt securities. Based upon our current level of expenditures, we believe our current working capital, together with cash flows from operating activities, will be more than adequate to meet our anticipated cash requirements for working capital, debt service and capital expenditures for at least the next 12 months.

Net cash used in operations totaled \$1.7 million in 2010, primarily due to our net loss before depreciation, amortization and stock based compensation. Net cash provided by investing activities amounted to \$8.4 million in 2010 and is primarily due to maturities of securities available-for-sale, partially offset by purchases of securities available-for-sale and property and equipment. Net cash used in financing activities amounted to less than \$0.1 million in 2010, which primarily represents the repurchase of our common stock under Rule 10b-18 plan. On February 4, 2009, our board of directors authorized a stock buyback program to repurchase up to an aggregate of \$2.0 million of our issued and outstanding common shares. The timing of stock repurchases and the number of shares of common stock to be repurchased has been, and will be made, in compliance with Rule 10b-18 under the Securities Exchange Act of 1934 and will depend upon market conditions, applicable legal and contractual requirements, and other factors. Purchases under this program to date totaled \$1.0 million as of December 31, 2009 and the nine month period ended September 30, 2010, respectively.

Critical Accounting Policies

Management's discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which are prepared in accordance with accounting principles that are generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to revenue recognition and inventory valuation. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. The accounting policies are the same as those described in the summary of significant accounting policies in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2010.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposure to market risk due to changes in interest rates relates primarily to the increase or decrease in the amount of interest income we can earn on our investment portfolio. Our risk associated with fluctuating interest rates is limited to our investments in interest rate sensitive financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. A 100 basis point adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive financial instruments. Changes in interest rates over time will increase or decrease our interest income.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures and internal controls that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our

Edgar Filing: DIGIRAD CORP - Form 10-Q

Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures and internal controls, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, and not absolute, assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures and internal controls.

Table of Contents

As required by the Securities and Exchange Commission Rule 13a-15(e) and Rule 15d-15(e), we carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the third quarter of fiscal 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. As litigation and the administrative proceedings are inherently uncertain, we cannot predict the outcome of such matters. While the ultimate outcome of litigation is always uncertain, we do not believe that it will have a material adverse effect on our business or financial results.

ITEM 1A. RISK FACTORS

There have been no material changes to the Risk Factors described under Part I Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on February 12, 2010, other than:

changes to the risk factor below entitled Recently enacted federal health care reform and follow-on regulations could adversely impact our business, which has been updated to reflect various potential changes to health care regulatory rules;

changes to the risk factor below entitled Our revenues may decline further due to reductions in Medicare reimbursement rates and/or increased third party payer certification requirements, which has been updated to reflect the recent developments in Medicare and private payer imaging reimbursements;

changes to the risk factor below entitled We spend considerable time and money complying with federal and state laws, regulations and other rules, and if we are unable to comply with such laws, regulations and other rules, we could face substantial penalties, which has been updated to reflect the recent mandates that require us to provide certain baseline of health benefits and premium contribution for our employees and their families; and

changes to the risk factor below entitled Our operations are highly dependent upon the availability of certain radiopharmaceuticals and third-party suppliers, thereby making us vulnerable to supply problems and price fluctuations, which could harm our business, which has been updated to reflect the recent developments with one of our sole suppliers of a key component of our gamma cameras.

We may incur additional losses due to the changing health care environment, the variable supply of radiopharmaceuticals and the downturn in the U.S. economy.

Our revenues have been impacted, and may be significantly further impacted, by the changing health care environment, the variable supply of radiopharmaceuticals and the downturn in the United States economy. All of these factors may drive greater pricing pressures on our personnel and equipment leasing services business from our competition or physician customers, further decrease the number of cameras that we are able to sell, or lead to disruptions in our supply chain; any or all of which could result in operating losses or negative cash flows. We cannot assure that an improvement in radiopharmaceutical supply or economic conditions would result in an immediate improvement in our operating results or cash flows. Furthermore, Congress has continued to defer resolution of certain medical regulatory reimbursement factors, creating an environment of uncertainty for our physician and healthcare entity customers.

Recently enacted federal health care reform and follow-on regulations could adversely impact our business.

Edgar Filing: DIGIRAD CORP - Form 10-Q

Laws were passed by the federal government in early 2010 that could fundamentally change how insurance companies and governmental programs reimburse our physician and healthcare entity customers for the provision of medical services, including the diagnostic imaging tests they perform using the products and services we sell or lease to them. These laws could negatively impact the demand for our services and/or require us to implement significant changes to our business models in how, where and whether we deliver our products and services. The expansion of the use of radiology benefit managers to pre-authorize and prevent diagnostic imaging, the requirement that physicians who provide advanced imaging in their offices provide patients with notices of alternative providers and the change in the mix of payers are among the factors that could negatively impact our volume of business or challenge our existing business models. Also, the creation of over 100 additional healthcare agencies in the new legislation could make it more difficult for our customers to make quick purchase decisions. There remains great uncertainty in the healthcare industry, as a whole, while we wait for regulations to be enacted, regulatory bodies to be formed, and the impact of the new legislation to be realized.

Various potential changes to health care regulatory rules could require us to change our operations significantly and could harm us financially. Nuclear medicine is a designated health service under the federal physician self-referral prohibition law known as the Stark Law, which states that a physician may not refer designated health services to an entity with which the physician or an immediate family member has a financial relationship, unless an exception applies. Our physician customers may be able to meet the *in-office ancillary services* exception to the Stark Law, appropriately supervise the individuals performing the nuclear imaging services and bill for them, and if the services are performed in the same building in which the physicians regularly practice medicine. From time to time, the Centers for Medicare and Medicaid Services and Congress have proposed to modify the Stark regulations in a manner that may restrict physicians in some business

Table of Contents

arrangements from utilizing the in-office ancillary services exception to the Stark Law. Recent health care reform legislation now requires physicians who take advantage of the *in-office ancillary services* exception for certain designated health services to provide a list of alternative imaging providers to their patients. Increased enforcement efforts could also cause physician customers to opt out of using the *in-office ancillary services* exception to provide imaging in their office, but could also put us at a competitive advantage over our competitors who have not historically structured their lease arrangements taking into account these applicable regulations.

Our revenues may decline further due to reductions in Medicare reimbursement rates and/or increased third party payer certification requirements.

The success of our business is largely dependent on our customers' ability to build a financially viable imaging business either through the purchase of our imaging systems and/or utilizing our leased personnel and equipment and radiopharmaceuticals. Our customers have been faced (and continue to be faced) with the downward trend in Medicare reimbursement rates. Our customers who perform imaging services in their office also experience the continuing efforts by some insurance companies to reduce health care expenditures by hiring radiology benefit managers that often require physicians to obtain accreditations, additional certifications and refuse them entry into geographic imaging panels, and their continued efforts to restrict the use of mobile/portable or leased cameras. The radiology benefit managers are unregulated entities who often own or use imaging centers that compete with independent physicians that are empowered by the insurance company to authorize/deny panel admission for the competing independent physicians. The radiology benefit managers often refuse to provide written approvals/denials and the reasons for the denials to the physicians leaving them unable to appeal to the insurance company under the terms of their provider contracts or to state insurance agencies or medical boards. The federal government set aside monies in the 2009 recession recovery acts to hire these radiology benefit managers to provide image management services to Medicare/Medicaid.

Medicare/Medicaid reimbursement for imaging significantly declined in 2009 (ultrasound) and in 2010 (nuclear) and there remains uncertainty with respect to additional cuts that may be imposed by the implementation of the sustainable growth rate to all reimbursement codes. While nuclear imaging was cut approximately 26% in 2010, (originally 36% in January 2010 offset by a retroactive correction to the practice expense relative value factor used by Centers for Medicare and Medicaid Services to calculate reimbursement in May 2010) and despite a temporary increase in all Medicare reimbursements of 2.2% effective from June 1, 2010 through November 30, 2010, the application of the sustainable growth rate could result in a further cut of 21.2% in reimbursements (or 22.4% including the expiration of the temporary increase). Congress has deferred application of the sustainable growth rate until December 1, 2010. These cuts have and would significantly impact the viability of in-office imaging performed by independent physicians. The reimbursement rates for hospitals and hospital related entities remain higher than the same procedures performed in physician offices. It is likely that private insurers would similarly adjust their reimbursements downward. The implementation of the sustainable growth rate has been deferred four times this year by Congress. It is unknown if this will be delayed again or if a permanent fix will be enacted. These cuts and pending cuts have resulted in cancellations of imaging days in our personnel and equipment leasing services business and the delay of purchase and lease decisions by our existing and prospective customers in our Product business. We have adjusted the fair market value of our personnel and equipment leasing services in light of this industry trend and there is potential further degradation in our pricing and customer volume.

Our business is not widely diversified.

We sell products and lease our imaging systems and personnel primarily in the cardiac nuclear and ultrasound imaging private practice markets. We began to diversify into the hospital and non-cardiac nuclear market this year. We may not be able to leverage our assets and technology to diversify our products and services in order to generate revenue beyond the cardiac nuclear and ultrasound imaging private practice markets in a timely manner. If we are unable to diversify our product and service offerings, our financial condition may suffer.

We compete against businesses that have greater resources and different competitive strengths.

The market for cardiac nuclear imaging cameras continues to decrease. Our competition has greater resources and a more diverse product offering than we do. Some of our competitors enjoy significant advantages over us, including greater name recognition, greater financial and technical resources, established relationships with healthcare professionals, larger distribution networks, and greater resources for product development, as well as marketing and sales. Additionally, certain medical device companies have developed alternative portable cameras that directly compete with our product offerings. If we are unable to expand our current market share, our revenues could decline.

In addition, our personnel and equipment leasing services customers may switch to other service providers. Our personnel and equipment leasing services segment competes against small local, owner operated or regional businesses, some of whom have the advantage of a lower cost structure, and against imaging centers that install nuclear gamma cameras and make them

Table of Contents

available to physicians in their geographic vicinity. If these competitors are able to win significant portions of our business, our sales could decline significantly. Our financial condition could be adversely affected under such circumstances.

Our operations are highly dependent upon the availability of certain radiopharmaceuticals and third-party suppliers, thereby making us vulnerable to supply problems and price fluctuations, which could harm our business.

Our personnel and equipment leasing service involves the use of radiopharmaceuticals. There have been significant disruptions in the supply of these radiopharmaceuticals this year, which has caused us to cancel services that would have otherwise been provided and has adversely affected our financial condition. Although the two major nuclear reactors supplying medical radiopharmaceuticals worldwide came back on-line in the third quarter of 2010, if we are unable to obtain an adequate supply of the necessary radiopharmaceuticals, we may be unable to lease our personnel and equipment through our in-office service operations and our business may be further harmed. Shortages can also cause price increases that may not be accounted for in third party reimbursement rates, thereby causing us to lose margin or require us to pass increases on to customers.

In addition, we rely on a limited number of third parties to manufacture and supply certain key components of our products. Alternative sources of production and supply may not be readily available or may take several months to scale-up and develop effective production processes. If a disruption in the availability of parts or in the operations of our suppliers were to occur, our ability to build gamma cameras could be materially affected. For this reason, we have backup plans in place that are designed to prevent delays in production. If these plans are unsuccessful, delays in the production of our gamma cameras for an extended period of time could cause a loss of revenue, which could significantly harm our business and results of operations.

In October 2010, the sole supplier of a key component of our gamma cameras informed us that they will close the plant that makes the component and will no longer supply the component to us after November 2010. We currently have a supply of the component that we expect will last until mid-2011. We are currently investigating alternative suppliers of the component and expect to engage another supplier by the end of 2010.

Failure to retain qualified technologists could limit our growth and adversely affect our business.

Our future growth and ability to generate profits depends, in part, upon our ability to identify, hire, and retain nuclear medicine technologists, cardiographic stress technicians, and ultrasound technologists, particularly those with multiple certifications in the ultrasound modality as these are individuals in high demand. The inability to retain such employees would diminish the knowledge and experience that we, as an organization, possess and might delay or prevent the achievement of our objectives. Hiring qualified technical personnel may be difficult due to the limited number of qualified candidates and the intense competition for these types of employees. Furthermore, we have historically suffered high employee turnover in regards to imaging technicians. If we are unable to consistently manage employee turnover, our business and financial condition may be adversely affected.

Our quarterly and annual financial results are difficult to predict and are likely to fluctuate from period to period.

We have historically experienced seasonality in our personnel and equipment leasing services business, as well as volatility due to the changing health care environment, the variable supply of radiopharmaceuticals, and the downturn in the U.S. economy. While our physicians are obligated to pay us for all lease days to which they have committed, our contracts permit some flexibility in scheduling when services are to be performed. We cannot predict with certainty the degree to which seasonal circumstances such as the summer slowdown, winter holiday vacations and weather conditions may affect the results of our operations. We have also experienced fluctuations in demand of our cardiac nuclear gamma cameras due to economic conditions, capital budget availability, or other financial or business reasons. In addition, due to the way that customers in our target markets acquire our products, a large percentage of our camera orders are booked during the last month of each quarterly accounting period. As such, a delivery delay of only a few days may significantly impact our quarter-to-quarter comparisons. Moreover, the sales cycle in our Product segment for our cameras is typically lengthy, which may cause us to experience significant revenue fluctuations. For these reasons, quarterly and annual sales and operating results may vary in the future. Therefore, period-to-period comparisons of our results of operations are not necessarily meaningful and should not be relied upon as indicators of future performance. Because of these and other factors, our operating results in one or more future reporting periods may fail to meet the expectations of securities analysts or investors, which could cause our stock price to decline significantly.

Our common stock is thinly traded and our options plan could affect the trading price of our common stock.

Our common stock is thinly traded and any significant sales of our common stock may cause volatility in our common stock price. We also have registered shares of common stock that we may issue under our employee benefit plans or from our treasury stock. Accordingly, these shares can

Edgar Filing: DIGIRAD CORP - Form 10-Q

be freely sold in the public market upon issuance, subject to restrictions under the securities laws. If any of these stockholders cause a large number of securities to be sold in the public market, the sales could reduce the trading price of our common stock. Although we are not aware of any single stockholder owning more than 9.99% of our stock, stockholders holding a significant amount of our common stock might be able to significantly influence matters requiring approval by our stockholders, possibly including the election of directors and the approval of mergers or other business combination transactions.

Table of Contents

We spend considerable time and money complying with federal and state laws, regulations and other rules, and if we are unable to comply with such laws, regulations and other rules, we could face substantial penalties.

We are directly, or indirectly through our physician customers, subject to extensive regulation by both the federal government and the states in which we conduct our business, including: the federal Medicare and Medicaid anti-kickback laws and other Medicare laws, regulations, rules, manual provisions, and policies that prescribe the requirements for coverage and payment for services performed by us and our physician customers; the federal False Claims statutes; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended in 2009 under the HITECH Act that places direct legal obligations and higher liability on us with respect to the security and handling of personal health information; the Stark Law; the federal Food, Drug and Cosmetic Act; federal and state radioactive materials laws; state food and drug and pharmacy laws and regulations; state laws that prohibit the practice of medicine by non-physicians and fee-splitting arrangements between physicians and non-physicians; state scope-of-practice laws; and federal rules prohibiting the mark-up of diagnostic tests to Medicare under certain circumstances. If our physician customers are unable or unwilling to comply with these statutes, regulations, rules, and policies, utilization rates of our services and products could decline and our business could be harmed. Additionally, new government mandates require us to provide a certain baseline of health benefits and premium contribution for our employees and their families or pay governmental penalties. Some of these costs are not tax deductible. Either option will result in additional costs to us and could negatively impact our cash reserves.

We maintain a compliance program to identify and correct any compliance issues and remain in compliance with all applicable laws, to train employees, to audit and monitor our operations, and to achieve other compliance goals. Like most companies with compliance programs, we occasionally discover compliance concerns. In such cases, we take responsive action including corrective measures when necessary. There can be no assurance that our responsive actions will insulate us from liability associated with any detected compliance concerns.

If our past or present operations are found to be in violation of any of the laws, regulations, rules, or policies described above or the other laws or regulations to which we or our customers are subject, we may be subject to civil and criminal penalties, damages, fines, exclusion from federal or state health care programs, or the curtailment or restructuring of our operations. Similarly, if our physician customers are found to be non-compliant with applicable laws, they may be subject to sanctions which could have a negative impact on us. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management's attention from the operation of our business, and damage our reputation.

Our manufacturing operations and executive offices are located at a single facility that may be at risk from fire, earthquakes or other disasters.

Our manufacturing operations, research and development activities and executive offices are located in a single facility in Poway, California, near known fire areas and earthquake fault zones. Any future natural disaster could cause substantial delays in our operations, damage to our manufacturing equipment, research and development efforts and inventory, and cause us to incur additional expenses. Although we have taken precautions to insure our facilities and continuing operations, this may not be adequate to cover our losses in any particular case. A disaster could significantly harm our business and results of operations.

The medical device industry is litigious, which could result in the diversion of our management's time and efforts, and require us to pay damages which may not be covered by our insurance.

Our operations entail risks of claims or litigation relating to product liability, radioactive contamination, patent infringement, trade secret disclosure, warranty claims, product recalls, property damage, misdiagnosis, personal injury, and death. Any litigation or claims against us, or claims we bring against others, may cause us to incur substantial costs, could place a significant strain on our financial resources, divert the attention of our management from our core business and harm our reputation. We may incur significant liability in the event of any such litigation, regardless of the merit of the action. If we are unable to obtain insurance, or if our insurance is inadequate to cover claims, our cash reserves and other assets could be negatively impacted. Additionally, costs associated with maintaining our insurance could become prohibitively expensive, and our ability to become profitable could be diminished.

Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.

Our success depends, in part, on our ability to protect our proprietary rights to the technologies used in our products. Our pending United States patent applications, which include claims to material aspects of our products and procedures that are

Table of Contents

not currently protected by issued patents, may not issue as patents in a form that will be advantageous to us. Any patents we have obtained or do obtain may be challenged by re-examination or otherwise invalidated or eventually found unenforceable. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Competitors may attempt to challenge or invalidate our patents, or may be able to design alternative techniques or devices that avoid infringement of our patents, or develop products with functionalities that are comparable to ours. In the event a competitor infringes upon our patent or other intellectual property rights, litigation to enforce our intellectual property rights or to defend our patents against challenge, even if successful, could be expensive and time consuming and could require significant time and attention from our management. We may not have sufficient resources to enforce our intellectual property rights or to defend our patents against challenges from others.

Anti-takeover provisions in our organizational documents, our Stockholders Rights Plan and Delaware law may prevent or delay removal of current management or a change in control.

Our restated certificate of incorporation and restated bylaws contain provisions that may delay or prevent a change in control, discourage bids at a premium over the market price of our common stock, and adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. The rights issued pursuant to our Stockholder Rights Plan will become exercisable, subject to certain exceptions, the tenth day after a person or group announces acquisition of 15% or more of our common stock or announces commencement of a tender or exchange offer, the consummation of which would result in ownership by the person or group of 15% or more of our common stock. In addition, as a Delaware corporation, we are subject to Delaware law, including Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as set forth in Section 203. These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On February 4, 2009, our Board of Directors approved a stock repurchase program whereby we may, from time to time, purchase up to \$2.0 million worth of our common stock in the open market, in privately negotiated transactions or otherwise, at prices that we deem appropriate. The plan has no expiration date. Details of purchases made during 2009 and the nine months ended September 30, 2010 are as follows:

	Total Number of Shares Purchased During the Period	Average Price Paid Per Share for Period Presented	Total Cumulative Number of Shares Purchased as Part of Publicly Announced Plan	Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan
Period:				
February 4, 2009 – February 28, 2009	8,700	\$ 0.98	8,700	\$ 1,991,474
March 1, 2009 – March 31, 2009	2,600	0.99	11,300	1,988,900
May 1, 2009 – May 31, 2009	183,500	1.26	194,800	1,758,352
June 1, 2009 – September 30, 2009	14,300	1.25	209,100	1,740,438
July 1, 2009 – July 31, 2009	33,200	2.14	242,300	1,669,307
August 1, 2009 – August 31, 2009	192,918	2.02	435,218	1,279,640
September 1, 2009 – September 30, 2009	14,000	2.11	449,218	1,250,085
November 1, 2009 – November 30, 2009	93,200	2.28	542,418	1,037,627
December 1, 2009 – December 31, 2009	5,000	2.38	547,418	1,025,739
February 1, 2010 – February 28, 2010	25,800	1.91	573,218	976,571
As of September 30, 2010:	573,218	\$ 1.79	573,218	\$ 976,571

In addition to the above purchases, John Sayward, a member of our board of directors and an affiliated purchaser as defined in Rule 10b-18(a)(3), purchased 20,000 shares of common stock in the open market at an average price of \$1.02 per share in February 2009.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

Table of Contents

ITEM 4. REMOVED AND RESERVED

ITEM 5. OTHER INFORMATION

None.

Table of Contents

ITEM 6. EXHIBITS

Exhibit Number	Description
3.1(1)	Restated Certificate of Incorporation
3.2(2)	Restated Bylaws
4.1(3)	Form of Specimen Stock Certificate
4.2(4)	Amended and Restated Investors Rights Agreement by and among Digirad Corporation and the investors listed on the schedule attached thereto, dated April 23, 2002, as amended
31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended
31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

- (1) This exhibit was previously filed as an exhibit to the Company's quarterly report on Form 10-Q originally filed with the Securities and Exchange Commission on August 11, 2004, as amended thereafter, and is incorporated herein by reference.
- (2) The exhibit was previously filed as an exhibit to the Company's quarterly report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2007, and is incorporated herein by reference.
- (3) This exhibit was previously filed as an exhibit to the Registration Statement on Form S-1 (File No. 333-113760) originally filed with the Securities and Exchange Commission on June 19, 2004, as amended thereafter, and is incorporated herein by reference.
- (4) This exhibit was previously filed as an exhibit to the Company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2004, and is incorporated herein by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DIGIRAD CORPORATION

Date: October 28, 2010

By: /s/ TODD P. CLYDE
Todd P. Clyde

President and Chief Executive Officer

(Principal Executive Officer)

Date: October 28, 2010

By: /s/ RICHARD B. SLANSKY
Richard B. Slansky

Chief Financial Officer

(Principal Financial and Accounting Officer)

Table of Contents

INDEX TO EXHIBITS

Exhibit Number	Description
3.1(1)	Restated Certificate of Incorporation
3.2(2)	Restated Bylaws
4.1(3)	Form of Specimen Stock Certificate
4.2(4)	Amended and Restated Investors Rights Agreement by and among Digirad Corporation and the investors listed on the schedule attached thereto, dated April 23, 2002, as amended
31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended
31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

- (1) This exhibit was previously filed as an exhibit to the Company's quarterly report on Form 10-Q originally filed with the Securities and Exchange Commission on August 11, 2004, as amended thereafter, and is incorporated herein by reference.
- (2) The exhibit was previously filed as an exhibit to the Company's quarterly report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2007, and is incorporated herein by reference.
- (3) This exhibit was previously filed as an exhibit to the Registration Statement on Form S-1 (File No. 333-113760) originally filed with the Securities and Exchange Commission on June 19, 2004, as amended thereafter, and is incorporated herein by reference.
- (4) This exhibit was previously filed as an exhibit to the Company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2004, and is incorporated herein by reference.